These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35842881)

  • 1. The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    J Neurol; 2022 Nov; 269(11):5991-6002. PubMed ID: 35842881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Secondary Treatment Failure during Incobotulinumtoxin-A Long-Term Treatment Demonstrated by the Drawing of Disease Severity.
    Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P; Samadzadeh S
    Toxins (Basel); 2023 Jul; 15(7):. PubMed ID: 37505723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin.
    Hefter H; Rosenthal D; Jansen A; Brauns R; Ürer B; Bigalke H; Hartung HP; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    J Neurol; 2023 Feb; 270(2):788-796. PubMed ID: 36195775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.
    Samadzadeh S; Ürer B; Brauns R; Rosenthal D; Lee JI; Albrecht P; Hefter H
    Toxins (Basel); 2020 Aug; 12(8):. PubMed ID: 32759685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study.
    Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P
    J Neurol; 2020 May; 267(5):1340-1347. PubMed ID: 31960136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Pseudo"-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study.
    Hefter H; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056396
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term therapy with botulinum toxin in facial synkinesis: Retrospective data analysis of data from 1998 to 2018.
    Alipour S; Pick C; Jansen S; Rink S; Klußmann JP; Grosheva M
    Clin Otolaryngol; 2021 Jul; 46(4):758-766. PubMed ID: 33534183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.
    Hefter H; Samadzazeh S; Rosenthal D
    J Neurol; 2021 Jan; 268(1):206-213. PubMed ID: 32761340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
    Danchenko N; Johnston KM; Whalen J
    J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.
    Hefter H; Schomaecker I; Schomaecker M; Ürer B; Brauns R; Rosenthal D; Albrecht P; Samadzadeh S
    Toxins (Basel); 2023 Jun; 15(7):. PubMed ID: 37505701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.
    Petracca M; Lo Monaco MR; Ialongo T; Di Stasio E; Cerbarano ML; Maggi L; De Biase A; Di Lazzaro G; Calabresi P; Bentivoglio AR
    J Neurol; 2023 Jan; 270(1):340-347. PubMed ID: 36068376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia.
    Hefter H; Rosenthal D; Bigalke H; Moll M
    Ther Adv Neurol Disord; 2019; 12():1756286419892078. PubMed ID: 31897089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA.
    Hefter H; Samadzadeh S; Moll M
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33121133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins.
    Hefter H; Hartmann CJ; Kahlen U; Samadzadeh S; Rosenthal D; Moll M
    Front Neurol; 2021; 12():636590. PubMed ID: 33633680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.
    Hefter H; Spiess C; Rosenthal D
    J Neural Transm (Vienna); 2014 May; 121(5):513-9. PubMed ID: 24311063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.